| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500001 | 1 mg | $400 | ||
| 500002 | 5 mg | $800 | ||
| 500003 | 20 mg | $2200 |
| Clone | Abatacept |
|---|---|
| Application | Flow cytometry, animal model study |
| Host Species | Mammalian cells |
| Format | Liquid |
| Product Description | Abatacept Biosimilar |
| Isotype | N/A |
| Regulatory Status | RUO |
| Clonality | Recombinant |
| Species specificity | Human |
| Purity | >95% by reducing SDS-PAGE |
| Grade | In vivo |
| Storage Conditions | 4ºC |
| Maximal Shelf Life | 12 months |
| Synonyms | CD152 |
| See All Formats | Clone Abatacept |
Abatacept is a recombinant fusion protein engineered to specifically interfere with T-cell activation pathways. Structurally, it consists of the extracellular domain of cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4, also known as CD152) fused to the modified Fc region of human immunoglobulin G1 (IgG1). This fusion creates a single, stable glycoprotein molecule with both binding and effector-modulating properties. The molecular weight of Abatacept is approximately 92 kilodaltons (kDa).
The CTLA-4 domain of Abatacept retains high affinity for CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs). This binding is competitive with the natural T-cell surface receptor CD28, which normally interacts with CD80/CD86 to deliver a critical costimulatory signal required for full T-lymphocyte activation. By occupying these ligands, the CTLA-4 component effectively blocks T-cell costimulation, thereby inhibiting the cascade of downstream immune responses. The immunoglobulin Fc fragment in Abatacept contributes to molecular stability, prolongs serum half-life through neonatal Fc receptor (FcRn) recycling, and facilitates purification through Protein A affinity, but it is engineered to minimize unwanted immune effector functions such as complement activation or antibody-dependent cytotoxicity.
CTLA-4 Fc Fusion Protein (Abatacept Biosimilar) TDS
Have a product or application question? Consult our FAQs or contact us.
